Thyroid Cancer Stage IVB (Papillary/Follicular)
Reviewed by Oncology Team, HealOnco | Last updated: 2026-04
What Stage IVB (Papillary/Follicular) Means
Distant metastases (M1): pulmonary, osseous, brain, etc.
Treatment Approach for Stage IVB (Papillary/Follicular)
RAI ablation if disease is RAI-avid (repeat 131-I therapy every 3–6 months if uptake present). TSH suppression maximum. Targeted therapy: lenvatinib (oral multi-tyrosine kinase inhibitor; improved OS in DECISION trial) 24 mg daily OR sorafenib (alternative TKI) 400 mg BID. Immunotherapy emerging (pembrolizumab for advanced/metastatic, especially if BRAF V600E+ or MSI-H, but limited data). Supportive care, bone metastases management, pain control.
Survival Rates and Prognosis
The 5-year survival rate for thyroid cancer at Stage IVB (Papillary/Follicular) is approximately 10-year survival 10–40%; papillary with pulmonary mets more indolent (median OS >10 years); anaplastic with mets median OS <6 months.. Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.
Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.
How Other Stages Compare
| Stage | 5-Year Survival | Treatment |
|---|---|---|
| Stage I (Papillary/Follicular, age <55 years) | 10-year survival >95%; recurrence-free survival 80–90% with multimodal therapy (surgery + RAI if indicated). | Near-total or total thyroidectomy; radioactive iodine ablation if… |
| Stage I (Papillary/Follicular, age ≥55 years) | 10-year survival 90–95%; lower than age <55 due to comorbidities, competing mortality. | Near-total or total thyroidectomy ± RAI (individualize based on tumor… |
| Stage II (Papillary/Follicular, age ≥55 years) | 10-year survival 80–90%; extrathyroidal extension worsens outcomes. | Total thyroidectomy with lymph node dissection (central ± lateral if N1b);… |
| Stage III (Papillary/Follicular, age ≥55 years) | 10-year survival 50–70%; depends on extent of invasion, resectability, nodal involvement. | Total thyroidectomy with en bloc resection of invaded structures (larynx,… |
| Stage IVA (Papillary/Follicular, age ≥55 years) | 10-year survival 35–50%; prognosis worsens with distant spread. | Resection of primary + lymph node dissection if feasible. RAI ablation. EBRT… |
| Stage I–IV Medullary Thyroid Cancer (MTC) | Stage I: 10-year survival ~90%; Stage II: 70%; Stage III: 50%; Stage IV: 10–30%. Calcitonin doubling time (marker of disease progression) predicts survival. | Total thyroidectomy + central neck lymph node dissection… |
| Stage I–IV Anaplastic Thyroid Cancer (ATC) | Median overall survival untreated: 3–6 months; with aggressive multimodal therapy: 12–24 months in select patients. 5-year survival <5%. | Surgical resection if completely resectable (total thyroidectomy, lymph node… |
Thyroid Cancer Treatment in Top Cities
Diagnosed with Stage IVB (Papillary/Follicular) Thyroid Cancer?
Our specialists can review your reports and create a personalised treatment plan.
Get a Free Consultation